Company intelligence / Profile preview
Tissue Repair Ltd
Australiatissuerepair.com.au ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Completed Phase IIB clinical trials in 2020 with data analysis finalized in March 2021, showing promising efficacy for its proprietary technology. Planning to commence pivotal Phase III trials for TR-987 in 2024, subject to FDA approval.
- Therapeutic areas
- Dermatology
- Modalities
- Topical gelimmunogenic active ingredient
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Tissue Repair Ltd.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tissue Repair Ltd.